It has long been regarded as a tumor suppressor due to its frequent downregulation in sporadic tumors during invasion and metastasis1 and the high frequency of inactivating CDH1 mutations that are observed in diffuse gastric cancer (DGC) and lobular breast cancer (LBC). This evidence concerns the gene CDH1 and CDH1-related diffuse gastric and lobular breast cancer syndrome.